1234 Nzila A (2006) The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother 57:1043–1054 Nzila A, Mberu E, Bray P, Kokwaro G, Winstanley P, Marsh K, Ward S (2003) Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob Agents Chemother 47:2108–2112 Nzila A, Ward SA, Marsh K, Sims PF, Hyde JE (2005a) Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends Parasitol 21:292–298 Nzila A, Ward SA, Marsh K, Sims PF, Hyde JE (2005b) Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. Trends Parasitol 21:334–339 Ostor AJ (2005) Beyond methotrexate: biologic therapy in rheumatoid arthritis. Clin Med 5:222–226 Priest DG, Bunni MA (1995) In: Bailey LB (ed) Folate in health and disease. Marcel Dekker, New York, pp 379–403 Reggev A, Djerassi I (1986) Rescue from high-dose methotrexate with 5-methyltetrahydrofolate. Cancer Treat Rep 70:251–253 Sheehy TW, Dempsey H (1970) Methotrexate therapy for Plasmodium vivax malaria. JAMA 214:109–114 Sixsmith DG, Watkins WM, Chulay JD, Spencer HC (1984) In vitro antimalarial activity of tetrahydrofolate dehydrogenase inhibitors. Am J Trop Med Hyg 33:772–776 Suzuki Y, Wakabayashi T, Jackson K (2005) Methotrexate for therapy of rheumatoid arthritis. Nippon Rinsho 63(Suppl 1):498–502 Swierkot J, Szechinski J (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58:473–492 Tahar R, de Pecoulas PE, Basco LK, Chiadmi M, Mazabraud A (2001) Kinetic properties of dihydrofolate reductase from wild- Parasitol Res (2008) 102:1227–1234 type and mutant Plasmodium vivax expressed in Escherichia coli. Mol Biochem Parasitol 113:241–249 Toyoda T, Brobey RK, Sano G, Horii T, Tomioka N, Itai A (1997) Lead discovery of inhibitors of the dihydrofolate reductase domain of Plasmodium falciparum dihydrofolate reductase- thymidylate synthase. Biochem Biophys Res Commun 235:515–519 van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, Greenwood BM (1995) Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 89:672– 676 Wagner C (1995) In: Bailey LB (ed) Folate in health and disease. Marcel Dekker, New York Walter RD, Bergmann B, Kansy M, Wiese M, Seydel JK (1991) Pyrimethamin-resistant Plasmodium falciparum lack cross-resistance to methotrexate and 2,4-diamino-5-(substituted benzyl) pyrimidines. Parasitol Res 77:346–350 Walzer PD, Foy J, Steele P, White M (1992) Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob Agents Chemother 36:1943–1950 Wang P, Sims PF, Hyde JE (1997) A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology 115:223–230 Wang P, Wang Q, Sims PF, Hyde JE (2007) Characterisation of exogenous folate transport in Plasmodium falciparum. Mol Biochem Parasitol 154:40–51 Wildbolz A (1973) Methotrexate in the therapy of malaria. Ther Umsch 30:218–222